Arthritis Unit, Department of Rheumatology, Hospital Clinic, University of Barcelona, Villarroel 170, Stairway 11, 2nd Floor, 08036, Barcelona, Spain.
Mod Rheumatol. 2012 Aug;22(4):602-4. doi: 10.1007/s10165-011-0550-4. Epub 2011 Nov 18.
Therapy with TNF blockers may induce cutaneous adverse events, but the development of morphea, a localized scleroderma lesion, is extremely infrequent. We describe a 37-year-old man with ankylosing spondylitis treated with adalimumab who developed morphea lesions in the lower limbs after 12 months of treatment. Adalimumab was discontinued, which resulted in progressive improvement in the skin lesions, with only mild hyperpigmentation remaining. We also review reports of morphea and other adverse cutaneous events related to anti-TNF treatment.
TNF 阻滞剂治疗可能会引发皮肤不良反应，但局限性硬皮病病变硬斑病的发生极其罕见。我们描述了一位 37 岁男性强直性脊柱炎患者，使用阿达木单抗治疗 12 个月后下肢出现硬斑病病变。阿达木单抗被停用，皮肤病变逐渐改善，仅残留轻度色素沉着。我们还回顾了与抗 TNF 治疗相关的硬斑病和其他不良皮肤事件的报告。
